TMED9-Binding Agents for Toxic Proteinopathy Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective treatments for toxic proteinopathies caused by genetic mutations leading to protein misfolding and accumulation, which trigger cellular stress and disease progression in conditions like MUC1-associated kidney disease, Retinitis Pigmentosa, and autosomal dominant tubulo-interstitial kidney disease.
Innovation Solution
The compound (±)-2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane (BRD-4780) is identified to treat or prevent toxic proteinopathies by releasing mutant proteins from the early secretory pathway, specifically binding to the TMED9 cargo receptor, promoting anterograde trafficking and lysosomal degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mutant proteins accumulate in the early secretory pathway, then toxic proteinopathies are caused, but no effective treatments are available
Solution Approach 1:
The patent uses chemical compounds (such as 4-phenyl-1,2,3,4-tetrahydroisoquinoline derivatives) as intermediary substances that bind to mutant proteins in the early secretory pathway. These compounds act as mediators to facilitate the release and degradation of toxic protein aggregates, thereby treating proteinopathies without requiring direct genetic intervention.
Solution Approach 2:
The invention changes the chemical and physical parameters of the mutant proteins by introducing small molecule compounds that alter protein-protein interactions. This changes the state of mutant proteins from aggregated/toxic forms to releasable/degradable forms, enabling their clearance from the secretory pathway.
2Object-affected harmful factors
If mutant proteins are retained in the secretory pathway, then cellular stress increases, but clearing mechanisms are insufficient
Solution Approach 1:
The patent enables the cell's own degradation systems to clear mutant proteins by using compounds that release retained proteins from the secretory pathway. The cell's existing proteolytic mechanisms then handle the degradation, making the system self-service rather than requiring external intervention for each degradation event.
Solution Approach 2:
Chemical compounds serve as intermediaries that bridge the gap between retained mutant proteins and cellular degradation systems. These compounds facilitate the handoff of mutant proteins to clearance mechanisms, improving the efficiency of protein removal and reducing cellular stress.
3Reliability
If genetic mutations cause protein misfolding, then disease progression occurs, but therapeutic options are limited
Solution Approach 1:
The patent describes a universal class of chemical compounds (4-phenyl-1,2,3,4-tetrahydroisoquinoline derivatives) that can treat multiple different proteinopathies caused by various genetic mutations. This single compound class addresses diverse diseases including retinitis pigmentosa, kidney disease, and neurodegenerative disorders, providing versatile therapeutic coverage.
Solution Approach 2:
The invention changes the therapeutic approach from gene-specific treatments to a broader chemical intervention that addresses the common mechanism of protein misfolding and retention. By targeting the downstream effect of mutations (protein aggregation in secretory pathway) rather than the mutations themselves, the therapy becomes adaptable to multiple genetic causes.
Data Source
AI summary
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.